David Stevens, CEO, Peacocks Medical Group
David Stevens, CEO, Peacocks Medical Group

Orthotics provider Peacocks Medical Group (PMG) is marking a significant milestone in its 123-year history with a series of announcements that represent its most ambitious period of growth and investment yet and includes the launch of its own branded product range.

Having doubled in size over the past five years, the company has opened a second state-of-the-art manufacturing facility in Sheffield – complementing its long-established headquarters and manufacturing base in Newcastle – alongside the launch of its own brand product range and a series of exclusive UK distribution agreements with leading clinical product manufacturers.

The 4,000 square foot Sheffield facility, which opened early July 2026, will meet growing demand across PMG’s expanding national NHS contract portfolio. With over 47 dedicated clinicians embedded within NHS partner Trusts across the UK and more than 60 skilled technicians operating from its Newcastle site, the company has the clinical and technical infrastructure to deliver at scale. Sheffield will increase that capacity by 30 per cent.

The new site also marks PMG’s commitment to next-generation manufacturing. Both facilities are transitioning to high-technology, automated production methods — incorporating 3D manufacturing technology and robotics. This investment is not incremental but is a fundamental shift in how PMG makes products, designed to ensure patients receive what they need, on time, every time.

Advertisement | Continue story below

Alongside its manufacturing expansion, PMG is launching its own branded product range and entering into a number of exclusive UK distribution agreements with specialist manufacturers and products such as Wellwalking, Fito, On Zen and MediRoyal, with several other agreements in advanced stages.

These partnerships bring new clinical technologies, data-driven cost-effective products and expanded patient choice to PMG and NHS clinicians and commissioners.

Together, these additions enable access to a broader, more sophisticated product offering, curated, quality-assured and supported by PMG’s clinical expertise.

David Stevens, CEO at Peacocks Medical Group, said: “This is a defining moment for Peacocks Medical Group. Our growth over the past five years reflects the trust that NHS partners have placed in us and this investment is our commitment to earning more of it.

“With Sheffield operational, our technology programme under way and a genuinely exciting product range coming to market, we are better placed than ever to deliver for patients.

“With a national footprint, a 123-year heritage and a clear strategy for the years ahead, Peacocks MedicaL Group enters this next phase as a stronger, faster and more capable organisation – one built to deliver life-changing orthotics to more patients, better.”

THIIS ROUND-UP
Join the 3,750+ mobility professionals who stay informed with THIIS' twice-weekly industry updates.
We respect your privacy
https://thiis.co.uk/wp-content/uploads/2026/07/dan.jpghttps://thiis.co.uk/wp-content/uploads/2026/07/dan-150x150.jpgLiane McIvorNewsroomSupplier NewsTrade Newsexpansion,Growth,orthotics,Peacocks Medical GroupOrthotics provider Peacocks Medical Group (PMG) is marking a significant milestone in its 123-year history with a series of announcements that represent its most ambitious period of growth and investment yet and includes the launch of its own branded product range. Having doubled in size over the past five years,...News, views & products for mobility, access and independent living professionals